BRISTOL, Tenn., Jan. 5 (UPI) -- King said Thursday it has begun a phase 2 trial of its topical drug MRE0094 for chronic, neuropathic diabetic foot ulcers.
MRE0094, an adenosine A2A receptor agonist that blocks inflammation and enhances wound healing, appeared safe and showed signs of positive effects in a phase 1 study, the Bristol, Tenn.-based company said.
"We are very excited about the potential of MRE0094 as a safe and effective treatment for chronic, neuropathic, diabetic foot ulcers," Michael K. Jolly, King's executive vice president of research and development, said in a statement.
King said chronic, neuropathic, diabetic foot ulcers affect over 6 percent of the U.S. population and the incidence of diabetes is increasing by 1.3 million new cases diagnosed each year. The company estimates the U.S. wound healing market to be greater than $3 billion.
